Texas HIV Medication Program

Apply | Questions? | Contact Us

The Texas HIV Medication Program (THMP) provides medications for the treatment of HIV and its related complications for low-income Texans. To qualify for medications, potential clients who meet eligibility criteria complete an application for assistance. Once approved, a client receives medications at an assigned pharmacy in their community.

To learn more about the THMP and find out if you are eligible, see the Frequently Asked Questions. You can apply for the program by downloading and completing the client application. Be sure and review the specific “application instructions” when completing the application. The application and its instructions are located on the THMP document page. If you have more questions or need assistance completing your application, call the THMP toll-free at 800-255-1090.

The THMP is the official AIDS Drug Assistance Program (ADAP) for the State of Texas. The THMP has been in existence since 1987 and provides medications approved by the Food and Drug Administration (FDA) for the treatment of illnesses caused by the human immunodeficiency virus (HIV) and other opportunistic infections in HIV-infected individuals as prescribed by their doctor. THMP also operates the Texas HIV State Pharmaceutical Assistance Program (SPAP), which helps HIV-positive individuals that do not qualify for the full Low-Income Subsidy (extra help) with their out-of-pocket costs associated with Medicare Part D prescription drug plans, including co-payments, deductibles, coinsurance, and during the coverage gap (the "donut hole").

Texas HIV Medication Program Notifications

DSHS has three important notifications for clients participating in THMP. Please review the information provided and contact us at 1-800-255-1090 or hivstd@dshs.texas.gov if you have any questions.

First, beginning April 1, 2023, THMP will use a new method to determine eligibility for the program. The new method will create a more equitable and transparent eligibility process.

Currently, THMP determines financial eligibility by subtracting personal HIV drug costs from a person’s income. Beginning April 1, 2023, THMP will determine financial eligibility by subtracting $12,240 from a person’s income. This standard deduction is the average drug cost per THMP client. The standard deduction will be $12,240 for this first year, from April 1, 2023, to March 31, 2024. Each year, THMP will adopt a new standard deduction amount of the average client drug cost.

If you are a new client, THMP will use this new eligibility effective April 1, 2023. If you are an existing client, THMP will use the standard deduction to determine your eligibility during your annual recertification period. If your recertification period is after April 1, 2023, your eligibility will remain the same until your next annual recertification. At that time, THMP will use the new method to determine your eligibility.

You should contact your case worker to understand how this change will affect you. You can find the notification at Texas DSHS HIV/STD Program - Texas HIV Medication Program.

Second, THMP will reinstate the ten medications below, effective April 1, 2023.

These medications will be available to new and existing enrollees beginning April 1, 2023. Existing participants will receive a letter by March 1, 2023, informing them that these medications are now available.

Please share this information with those you know this change may impact.

Third, if you are a current Take Charge Texas (TCT) user and would like to provide feedback on future enhancements, contact THMP at hivstd@dshs.texas.gov and include “TCT Feedback” in the subject line.

THMP will invite those who email to see demonstrations of future system enhancements and give you the opportunity to provide feedback upon viewing the demonstration.

New Dosages of Three Medications Used To Treat HIV in Infants and Children Have Been Approved for Addition to the THMP Formulary

New dosages of three medications used to treat HIV in infants and children have been approved by the Department of State Health Services (DSHS) Commissioner of Health in addition to the Texas HIV Medication Program (THMP) AIDS Drug Assistance Program (ADAP) Formulary:

• Tivicay PD (dolutegravir) 25 mg
• Isentress (raltegravir) 25 mg
• low-dose Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg)

DSHS was able to estimate the fiscal impact of this change with reasonable certainty based on current data related to pediatric client loads and medication usage. The estimated fiscal impact of this change is minimal, with the possibility of a resulting positive fiscal impact when compared with maintaining only the current pediatric options. Consequently, DSHS is able to support these additions within existing monies and has approved adding these pediatric medications to the formulary.

The THMP formulary has been updated.

Please submit a new THMP Medical Certification Form (MCF) for any infants and children in need of these new medication doses.

Thanks to the Medication Advisory Committee for recommending these changes.

Formulary Addition

A medication has been added to the THMP Formulary:

• Rukobia (fostemsavir tromethamine), 600 mg tablets, #60 per bottle

The Medical Certification Form and THMP Formulary have been updated. Both can be found on the THMP documents page.

Program applications, guidelines, and formulary listings are available on the THMP document page.

THMP Email List

Sign up to one or more email lists below today to receive timely and relevant news from THMP:

Subscribe to THMP News - Less frequent updates with news about significant events for the THMP program.

Subscribe to THMP Participating Pharmacies - Updates of interest to THMP participating pharmacies.

Subscribe to THMP Eligibility - Information for ADAP Enrollment Workers and others who assist clients in THMP application submission and their supervisors.